Last reviewed · How we verify
NCT04160559
Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
NA trial testing green tea in Non-small Cell Lung Cancer. Withdrawn.
30 October 2020
Quick facts
| Lead sponsor | Xinqiao Hospital of Chongqing |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 11 January 2020 |
| Primary completion | 30 October 2020 |
| Estimated completion | 30 October 2020 |
| Sites | 2 locations across China |
Drugs / interventions tested
- green tea — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
Xinqiao Hospital of Chongqing
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with non-small cell lung cancer who met the inclusion and exclusion criteria were screened and randomly divided into control group and experimental group. Control group: chemotherapy plus water ,test group: chemotherapy plus green tea. Primary endpoint: Assessment of changes in quality of life (QOL) after chemotherapy according to FACT-L (4th edition). A clinically significant change in the quality of life of lung cancer was defined as a FACT-L score change of ≥6 points from baseline, with \<6 points defined as no clinically significant changes;
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04160559
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of green tea
Trials testing the same drug.
- NCT05681325 — Evaluation of Antioxidant and Anti-inflammatory Effect of Matcha Tea Intake on Periodontal Health · NA · unknown
- NCT00685516 — Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery · NA · completed
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other Xinqiao Hospital of Chongqing trials
Trials by the same sponsor.
- NCT07347626 — Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis · Phase 3 · not yet recruiting
- NCT07349836 — Application of mRNA Immunotherapy Technology in EB Virus Related Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07362758 — Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07349849 — Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT06987305 — Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04160559 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xinqiao Hospital of Chongqing
- Last refreshed: 8 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04160559.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing